CG-T1 / Caregen - LARVOL DELTA

…Caregen announced that it has filed substance patents for its internally developed dry eye treatment candidate ‘CG-T1’ in 31 major countries worldwide, including the United States, European Union (EU), China, Brazil, Russia, and Japan. (Business Korea) - "Caregen plans to enter Phase 2 clinical trials in earnest during the first quarter of next year. In this clinical trial, the company will verify clinical significance focusing on safety, efficacy, and dose response in actual dry eye disease patients."

New P2 trial • Patent • Dry Eye Disease